negative cognitive bias (BD II patients usually present for MDE), clinician skills, use of structured vs semistructured (better) interviews, and lack of information from family members (5, 6) .
I have tested some of the Ghaemi and others' bipolarity signs to find out whether, during MDE assessment, these signs could be useful to induce clinicians to carefully assess past hypomania, thus reducing BD II underdiagnosis and mistreatment (1) .
I describe the study methods in detail in previous reports (2, 4, (7) (8) (9) . I interviewed a consecutive sample of 260 outpatients with BD II and 173 drug-free outpatients with unipolar disorder who presented for MDE treatment in a private clinic in Italy. These samples are more representative of mood disorders, which are usually treated in clinical practice vs tertiary care centres (10, 11) . I used the Structured Clinical Interview for DSM-IV (12) . Systematic assessment of past hypomania was improved by more probing for overactivity and for information from family members; it resulted in increased BD II diagnoses (13, 14) . I assessed hypomania symptoms during MDE. The BD II group comprised 68.4% women, with a mean (SD) age of 41.7 (14.0) years. Of these patients, 81.1% presented with > 3 MDEs, with a mean (SD) MDE onset-age of 22.9 (10.8) years; 53% had atypical features; 59.2% showed depressive mixed state (DMX) (that is, MDE and > 2 concurrent hypomania symptoms, recently found to be very common in BD II [2, 4, 7] ); and 54.1% a family history of BD I and II (assessed by structured interview) (15) . Of the unipolar disorder group, 60.6% were women; the mean (SD) age was 47.0 (15.6) years; 58.9% had > 3 MDEs, with a mean (SD) onset-age of 32.0 (14.5) years; 25.4% had atypical features; 29.4% showed DMX; and 21.2% had a family history of BD. Sensitivity (SE) and specificity (SP) for predicting BD II were calculated by logistic regression for some signs of bipolarity (1). The results are as follows: > 3 MDEs (SE = 81.1%, SP = 41.0%), onset < 25 years (SE = 66.9%, SP = 64.1%), atypical features (SE = 53.0%, SP = 74.5%), DMX (SE = 59.2%, SP = 70.5%), and family history of BD (SE = 54.1%, SP = 78.7%). Family history of BD had the highest specificity (that is, few false positives). Family history, however, can be difficult to assess (3) . Conversely, 2 cross-sectional bipolarity signs that are not memory dependent-atypical features and DMX-also had high specificity and were not difficult to assess during MDE assessment (7, 8) . In a busy clinical practice, these 2 cross-sectional markers of BD II can induce clinicians to carefully probe for past hypomania. Results not only support Ghaemi and others' BSD but also suggest some clinical and family history markers to reduce BD II underdiagnosis.
Franco Benazzi, MD Forlì, Italy

Re: Clinical and Family History Markers of Bipolar II Disorder
Dear Editor:
We thank Dr Benazzi for his letter. He reviews previous studies that support associations between what we call bipolar spectrum disorder (BSD) and early-onset, atypical features, and mixed mood symptoms. He also applies our proposed definition to its first empirical test and finds excellent sensitivity for recurrent depressive episodes (3 or more), together with good specificity for atypical depressive features and mixed mood symptoms. We appreciate Dr Benazzi's careful empirical assessment. This is exactly the kind of empirical test that we hoped our heuristic definition of BSD would stimulate. We only hope that Dr Benazzi and other investigators will continue these studies, so that the criteria can be further refined empirically.
We wish to highlight 2 aspects of our proposal. On the one hand, we describe features of depressive symptoms, course, family history, and treatment response. We propose that these features outline a group of depression patients who have neither classic unipolar nor classic bipolar disorder (BD); that is, they never display spontaneous mania or hypomania. However, a unipolar diagnosis broad enough to encompass such patients may offer little in the way of predictive validity. These patients, in fact, have many more diagnostic features in common with BD than with unipolar depression. We therefore suggest the term BSD for this group, and we advocate empirical tests of our definition. Conversely, as Dr Benazzi also emphasizes, our proposed definition can be seen as a way of assessing patients who may be at high risk for having BD or later developing the disorder, especially BD II. If patients have many of the bipolar spectrum depressive features we highlight, closer examination may reveal past episodes of hypomania (or sometimes even mania) that either have been denied or have escaped detection. Further, such patients may be at high risk for future spontaneous hypomanic or manic episodes and thus may warrant careful assessment for such symptoms longitudinally. Hence, our list of bipolar spectrum symptoms can also be seen as clues for bipolarity that, if present, warrant an even more extensive evaluation for hypomanic or manic symptoms in a patient who does not appear to have BD.
In any case, we wish to emphasize that these are testable hypotheses, and we welcome and request the type of empirical examination that Dr Benazzi has inaugurated. Nassir Ghaemi, MD; James Y Ko, AB; Frederick K Goodwin, MD Cambridge, Massachusetts
Effect of Olanzapine on the Liver Transaminases
Dear Editor:
The effect of olanzapine on liver transaminases is among the less frequently encountered side effects of this novel atypical antipsychotic drug. Initial clinical trials observed a transient, asymptomatic, non-dose-dependent elevation in the liver transaminases in 9.4% of olanzapine-treated patients (1) .
Although this suggests an increased risk for hepatitis, it has been argued that there has been no evidence of hepatitis in the patients (2) . Some reports suggest that an even smaller percentage-1.9% in more than 2000 patients receiving olanzapine-had elevated enzyme levels, which gradually declined with continued treatment (3).
The Canadian Adverse Drug Reaction Monitoring Program (CADRMP), however, has received 9 reports of olanzapine causing mainly mild increases in alanine aminotransferase (ALT).
We report 2 cases wherein olanzapine caused significant elevation of liver transaminases, up to 5 times the normal reference range.
The first case is a woman, age 37 years, who presented with auditory hallucinations and religious delusions. This was her first psychotic episode postpartum. On admission, her liver transaminases were minimally elevated (ALT = 95 U/L > asparate aminotransferase [AST] 50 U/L). The normal range is ALT = 7 U/L to 40 U/L and AST = 7 U/L to 40 U/L. She had been taking 5 mg daily of olanzapine prior to admission, and the enzyme levels prior to initiation of olanzapine were not known. The dosage was increased to 10 mg daily, and liver transaminases were closely monitored. The enzymes continued to increase rapidly to about 4 to 5 times the normal reference range (ALT 237 U/L max) over the next 10 days. The drug was discontinued, and the enzyme levels gradually normalized after 4 days.
In the second case, a woman aged 62 years, with a long history of schizophrenia, did not respond to risperidone and was switched to olanzapine. She had been on 5 mg daily of olanzapine, which her primary psychiatrist in the clinic gradually increased to 15 mg daily. After she had been on olanzapine for a month, we incidentally found a significant increase in her liver transaminases (ALT = 179 U/L and AST = 115 U/L), following her hospitalization for delirium secondary to pneumonia. Olanzapine was then discontinued. For the next 4 days, her ALT fluctuated between 137 U/L and 180 U/L before it normalized.
Both these patients did not have any clinical evidence of liver dysfunction. The remainder of the liver panel was normal, except for a decrease in albumin in the second case, which normalized after stopping olanzapine. All other causes of elevation of liver transaminases were ruled out.
The relevance of elevated transaminases remains controversial. Mild elevations have been reported with the use of olanzapine. However, relevance of marked increase in liver enzymes (> 3 to 4 times the normal reference range) remains to be elucidated.
It is unclear whether these patients can be rechallenged with this drug. Thus, further research is warranted to address the relevance of elevated enzymes.
